Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer

Author(s): Longyang Liu, Ke Hu, Zhaoyang Zeng, Caiqiu Xu, Jin Lv, Zhongqiu Lin, Bin Wen*

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 16 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Ovarian Cancer (OC) remains the first leading cause of gynecologic malignancy. The survival rate from Serous Ovarian Cancer (SOC) is very low, and the present prognostic predictors of SOC are not very sensitive or specific.

Objective: The present study aimed to investigate Microtubule-Actin Cross-Linking Factor 1 (MACF1) expression in SOC tissues (including paraffin-embedded and fresh tissues) and to assess its expression and significant value in patients with SOC.

Methods: A total of 18 fresh SOC tissues and their paired paratumor tissues were performed with reverse-transcription quantitative PCR analysis to detect MACF1 mRNA expression. Moreover, 175 paraffin-embedded SOC tissues and 41 paratumor tissues were assessed for MACF1 expression using immunohistochemistry.

Results: The mRNA and protein expression of MACF1, both were higher in cancer tissues than that in paratumor tissues, and the high expression of MACF1 was associated with shorter Recurrence Free Survival (RFS) and Overall Survival (OS) in patients with SOC. Furthermore, multivariate regression analysis showed that high MACF1 expression was an independent poor survival predictor of patients with SOC.

Conclusion: MACF1 is upregulated in SOC, and it may be used as a useful prognostic biomarker in SOC.

Keywords: Microtubule-actin cross-linking factor 1, ovarian cancer, overall survival, prognosis, recurrence-free survival, serous ovarian cancer.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2021
Published on: 24 May, 2021
Page: [66 - 72]
Pages: 7
DOI: 10.2174/1574892816666210211091543
Price: $65

Article Metrics

PDF: 50